Navigation Links
Drug-Coated Stents Go Head to Head
Date:9/13/2007

Data analysis suggests sirolimus-coated model is safer

THURSDAY, Sept. 13 (HealthDay News) -- A survey of trials of drug-coated stents finds that those coated with the medication siromilus appear to be somewhat safer than those coated with another drug, paclitaxel.

Analysis of 38 trials involving more than 18,000 participants suggest that "sirolimus-eluting stents appear to have the best overall profile, if you look at the entire picture," said lead researcher Dr. Peter Juni, head of the division of clinical epidemiology and biostatistics at the University of Bern in Switzerland.

There was one caveat, however: According to Juni, the studies were so varied in the types of patients given stents -- tiny mesh tubes that prop open arteries -- that it's not possible to say that everyone would be better off with a siromilus-coated model.

"We need to better understand if there are subgroups that benefit more from siromilus-eluting stents or perhaps subgroups that do not benefit at all from them," he said. "Future studies need to address the problem of the patient spectrum."

The difference was confined to the risk of heart attacks and restenosis -- a re-blockage of the reopened artery -- after the stents were implanted, said the report, which is published in the Sept. 15 issue of The Lancet.

The researchers also noted that the patient death rate was the same for those who got either one of the more expensive drug-coated stents, or a bare-metal stent.

However, the incidence of heart attacks was 19 percent lower in those getting a siromilus-coated stent than those getting a bare-metal stent, the team found. Heart attack risk was 17 percent lower in those getting the paclitaxel stent compared to the use of bare-metal devices.

The report may help settle the ongoing battle between the two stents, "mainly because the data set is so big," said Dr. Kirk Garratt, clinical director of interventional cardiovascular research at Lenox Hill Hospital in New York City. However, he agreed with the authors that "this mix of patients is really troubling. We need to isolate out subsets of patients."

The analysis included groups that differed widely, Garratt noted. "For example, there were 10 percent women in one trial, 80 percent in another," he said. "It seems troubling to make sweeping statements about safety on such widely varying patient populations."

Recent changes in cardiology practice may have also undermined the report's importance, Garratt added. Worries about restenosis surfaced about a year ago, he said, and have led to changes in medical practice. But the new analysis largely includes studies done before then.

"Our effort to reduce stent clotting is paying off," Garratt said, mostly through a concentration on dual therapy involving clot-preventing medications. Cardiologists are now very careful to have stent recipients take both Plavix and aspirin, which act on blood platelets to prevent clotting, he said.

"This report could mistakenly be taken in such a way to make someone choose product A over product B," Garratt said. "The power of observation in the study is not enough to make that sweeping of a change."

The use of drug-coated stents is also being limited, at least in his practice, said Dr. Joseph B. Muhlestein, professor of medicine at the University of Utah, Salt Lake City. "If the patient has a low risk of restenosis, we get by with a bare-metal stent," he said.

Muhlestein found some comfort in the relatively low rate of deaths and complications described in the report. "The situation perhaps is not as bad as we worried," he said.

Muhlestein's group has been working on its own safety analysis of drug-coated stents, he added. "The data do not go against the belief that the siromilus stent might be safer than the paclitaxel stent," the expert said.

More information

You can learn how a stent works by going to the American Heart Association.



SOURCES: Peter Juni, M.D., head, division of clinical epidemiology and biostatistics, University of Bern, Switzerland; Kirk Garratt, M.D., clinical director, interventional cardiovascular research, Lenox Hill Hospital, New York City; Joseph B. Muhlestein, M.D., professor, medicine, University of Utah, Salt Lake City; Sept. 15, 2007, The Lancet


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Drug-Coated Stent
2. Failure of Drug-Coated Stent
3. Stronger Backing for Drug-Coated Stents
4. Drug-Coated Stents – Proven to be More Effectiv
5. Drug-Coated Stents Work Better In Diabetic Patients After Angioplasty
6. Drug-coated heart stents under scrutiny, after study
7. Off-label and Untested Use of Drug-coated Stents Appears Widespread
8. Studies Reveal Inappropriate Use Of Drug-Coated Stents
9. Expandable metal stents used in digestive cancers
10. The Efficacy Of Newer Stents Questioned
11. Analyzing The Side Effects Of Sirolimus Stents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, ... design, development and manufacturing of collagen and mineral ... announced today that Bill Messer has ... Marketing to further leverage the growing portfolio of ... devices. Bill joins the Collagen Matrix ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
Breaking Medicine Technology: